A new oral anticoagulant: the 50-year challenge

It is rare for any drug introduced more than 50 years ago to remain unsurpassed today; yet the oral prevention and treatment of thrombosis are still achieved by the use of the vitamin K antagonists (coumarins), such as warfarin, which were introduced in the 1940s and 1950s. For these anticoagulants, careful monitoring of the effect is needed to avoid bleeding or loss of efficacy. On the basis of the need for improved oral anticoagulants, a goal was set in 1985 to develop a new oral anticoagulant that could replace the vitamin K antagonists. After providing some medical and historical context, this article discusses the challenges facing the multidisciplinary team of scientists who were involved in the project leading to the discovery of the anticoagulant ximelagatran (Exanta; AstraZeneca), the first oral direct thrombin inhibitor.

[1]  H Oschkinat,et al.  The interaction of thrombin with fibrinogen. A structural basis for its specificity. , 1992, European journal of biochemistry.

[2]  Robert Huber,et al.  The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989 .

[3]  J. Deinum,et al.  The Importance of Enzyme Inhibition Kinetics for the Effect of Thrombin Inhibitors in a Rat Model of Arterial Thrombosis , 1997, Thrombosis and Haemostasis.

[4]  E. Shaw,et al.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin. , 1979, Thrombosis research.

[5]  S. Carlsson,et al.  Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats. , 2002, Thrombosis research.

[6]  R. Huber,et al.  The refined 1.9 A crystal structure of human alpha‐thrombin: interaction with D‐Phe‐Pro‐Arg chloromethylketone and significance of the Tyr‐Pro‐Pro‐Trp insertion segment. , 1989, The EMBO journal.

[7]  S. Olsson,et al.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial , 2003, The Lancet.

[8]  V. Feigin,et al.  Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century , 2003, The Lancet Neurology.

[9]  M. Wolzt,et al.  Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects , 2003, European Journal of Clinical Pharmacology.

[10]  Ulf Bredberg,et al.  Animal pharmacokinetics of inogatran, a low‐molecular‐weight thrombin inhibitor with potential use as an antithrombotic drug , 1998, Biopharmaceutics & drug disposition.

[11]  D. Gustafsson.  Oral direct thrombin inhibitors in clinical development , 2003, Journal of internal medicine.

[12]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[13]  Jing Fang,et al.  Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. , 2002, The American journal of medicine.

[14]  B. Eriksson,et al.  Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement , 2003, Thrombosis and Haemostasis.

[15]  J. Lehmann.  HYPO-PROTHROMBINEMIA PRODUCED BY 3,3-METHYLENEBIS (4-HYDROXYCOUMARIN) AND ITS USE IN THE TREATMENT OF THROMBOSIS. , 1942, Science.

[16]  W. Weaver,et al.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.

[17]  A. Turpie,et al.  A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. , 2001, The New England journal of medicine.

[18]  L. Johansson,et al.  No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers , 2003, Clinical pharmacokinetics.

[19]  Per Artursson,et al.  Selective Paracellular Permeability in Two Models of Intestinal Absorption: Cultured Monolayers of Human Intestinal Epithelial Cells and Rat Intestinal Segments , 1993, Pharmaceutical Research.

[20]  R. Kikumoto,et al.  A Synthetic Thrombin Inhibitor Taking Extremely Active Stereo-Structure , 1979, Thrombosis and Haemostasis.

[21]  K. P. Link.  The Discovery of Dicumarol and Its Sequels , 1959, Circulation.

[22]  K. P. Link,et al.  Studies on the Hemorrhagic Sweet Clover Disease IX. The Effect of Diet and Vitamin K on the Hypopro-Thrombinemia Induced by 3,3???-Methylenebis (4-Hydroxycoumarin) in the RatOne Figure , 1942 .

[23]  S. Schulman,et al.  Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. , 2003, The New England journal of medicine.

[24]  B. Eriksson,et al.  A Dose-ranging Study of the Oral Direct Thrombin Inhibitor, Ximelagatran, and Its Subcutaneous Form, Melagatran, Compared with Dalteparin in the Prophylaxis of Thromboembolism after Hip or Knee Replacement: METHRO I , 2002, Thrombosis and Haemostasis.

[25]  T. Andersson,et al.  Ximelagatran, an Oral Direct Thrombin Inhibitor, Has a Low Potential for Cytochrome P450-Mediated Drug-Drug Interactions , 2003, Clinical pharmacokinetics.

[26]  F. Markwardt.  The development of hirudin as an antithrombotic drug. , 1994, Thrombosis research.

[27]  T. Steinmetzer,et al.  Advances in the development of thrombin inhibitors , 2001, Expert opinion on investigational drugs.

[28]  D. W. Murray,et al.  Heparin and the thrombosis of veins following injury , 1937 .

[29]  E. Di Cera.  Thrombin interactions. , 2003, Chest.

[30]  K. P. Link,et al.  STUDIES ON THE HEMORRHAGIC SWEET CLOVER DISEASE IV. THE ISOLATION AND CRYSTALLIZATION OF THE HEMORRHAGIC AGENT , 1941 .

[31]  N. W. Barker,et al.  A PREPARATION FROM SPOILED SWEET CLOVER: [3,3′-Methylene-Bis-(4-Hydroxycoumarin)] Which Prolongs Coagulation and Prothrombin Time of the Blood: A Clinical Study , 1942 .

[32]  K. Mann,et al.  Thrombin formation. , 2003, Chest.

[33]  F. R. Bettelheim.  The clotting of fibrinogen. II. Fractionation of peptide material liberated. , 1956, Biochimica et biophysica acta.

[34]  S. Carlsson,et al.  Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. , 1999, Thrombosis research.

[35]  H. Diener,et al.  Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischaemic Attack or Ischaemic Stroke (MATCH): Study Design and Baseline Data , 2003, Cerebrovascular Diseases.

[36]  J. Deinum,et al.  Design and synthesis of thrombin inhibitors , 1995, Letters in Peptide Science.

[37]  E. Ohman,et al.  Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. , 2001, Chest.

[38]  H. Scheraga,et al.  High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the A alpha chain of human fibrinogen. , 1989, Biochemistry.

[39]  L. Lapidus,et al.  Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. , 2002, Thrombosis research.

[40]  J. Westwick,et al.  Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. , 1982, British medical journal.

[41]  U. Eriksson,et al.  No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran , 2003, Clinical pharmacokinetics.

[42]  L. Johansson,et al.  Influence of Age on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.

[43]  David Gustafsson,et al.  The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. , 2003, Thrombosis research.

[44]  J. Lehmann.  HYPOPROTHROMBINÆMIA PRODUCED BY METHYLENE-BIS-(HYDROXYCOUMARIN): ITS USE IN THROMBOSIS , 1942 .

[45]  S. Pehrsson,et al.  Effects of Melagatran, a New Low-molecular-weight Thrombin Inhibitor, on Thrombin and Fibrinolytic Enzymes , 1998, Thrombosis and Haemostasis.

[46]  S. Bajusz,et al.  Inhibition of thrombin and trypsin by tripeptide aldehydes. , 2009, International journal of peptide and protein research.

[47]  U. Bredberg,et al.  Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[48]  H. White,et al.  Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions , 2002, Expert opinion on pharmacotherapy.

[49]  M. Blombäck,et al.  Synthetic peptides with anticoagulant and vasodilating activity. , 1969, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[50]  H. Mulec,et al.  Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran , 2003, Clinical pharmacokinetics.

[51]  B. Eriksson,et al.  The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study , 2003, Journal of thrombosis and haemostasis : JTH.

[52]  U. Eriksson,et al.  No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor , 2003, Clinical pharmacokinetics.

[53]  R. Kikumoto,et al.  Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion. , 1981, Biochemical and biophysical research communications.

[54]  U. Eriksson,et al.  In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. , 1997, Thrombosis research.

[55]  A Abrahamsson,et al.  The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. , 2001, Thrombosis research.

[56]  C. Mathew,et al.  Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia. , 2003, Blood.

[57]  M. Wolzt,et al.  Inhibition of Thrombin Generation by the Oral Direct Thrombin Inhibitor Ximelagatran in Shed Blood from Healthy Male Subjects , 2002, Thrombosis and Haemostasis.

[58]  Ulf Bredberg,et al.  Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects , 2003, European Journal of Clinical Pharmacology.

[59]  J. Walenga.  An Overview of the Direct Thrombin Inhibitor Argatroban , 2003, Pathophysiology of Haemostasis and Thrombosis.

[60]  Miller,et al.  CLINICAL STUDY The , 2022 .

[61]  J. Hirsh,et al.  Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. , 2001, Chest.

[62]  C. Colwell,et al.  Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. , 2003, The New England journal of medicine.